Navigation Links
Bioheart Makes Breakthrough in Critical Limb Ischemia Therapy with Stem Cells Obtained from Fat Tissue
Date:12/21/2009

ural repair of diseased vessels and tissues by using the patient's own cells. Bioheart's TGI system is able to be used in a number of cardiovascular treatments to aid in the recovery of a normal life. That is Bioheart's goal."

"The University Hospital Ostrava is extremely excited to be a part of this cutting-edge technology and welcomes the studies,'' said Dr. Vaclav Prochazka, MD, PhD, MSc, Head Physician of the Department of Interventional Neuroradiology and Angiology, Vice Director for Research and Development at University Hospital Ostrava, Czech Republic, who has been utilizing the cells for treating his patients. "We believe that this will bring new hope to many patients suffering from critical limb ischemia."

Recent studies have identified adipose tissue as an alternate source of stem cells. The procedure for getting adipose derived stem cells from the patient is simple and easily tolerable by the patient even immediately following a heart attack. Fat tissue, itself, is plentiful within the patient's own body and there is an abundance of stem cells within fat tissue. The stem cells can be separated from the fat cells very quickly with the TGI system, making treatment after an event, like a heart attack, efficient. That efficiency contributes to the success of the treatment.

In contrast, the alternative procedure is to use bone marrow to obtain stem cells, which is extremely painful and often yields a low volume of stem cells.

Bioheart is adding the lower limb ischemia treatment to its product portfolio, which seeks to eliminate cardiovascular problems through regeneration and prevention.

Bioheart's TGI 1200 System:

It is a fully-automated, point-of-care system that recovers potentially regenerative stem cells from a patient's own adipose tissue in about an hour, with minimal operator intervention. Adipose tissue is collected from the patient's abdomen and processed in the T
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Bioheart Inc. to Participate in the 2009 World Stem Cell Summit on September 23rd
2. Bioheart Strengthens Executive Team in Order to Accelerate Business Plan and Enhance Its Position in the Cardiovascular Stem Cell Therapy Industry
3. United States FDA Clears the REGEN Trial to Test Biohearts Combination Gene and Stem Cell Therapy in Heart Failure Patients
4. Bioheart, Inc. Announces Additional Funding Support
5. Bioheart, Inc. to Present at Red Chip Investor Conference in New York
6. Bioheart, Inc., Announces Letter of Intent to Acquire MEDICALGORITHMICS, Ltd.
7. Bioheart, Inc. Announces Financial Results for Second Quarter 2008
8. Bioheart, Inc. Announces Results of Annual Meeting
9. Bioheart, Inc., Announces Management Change
10. Bioheart, Inc. to Introduce At-Home Heart Failure Monitor for Congestive Heart Failure Patients
11. Bioheart, Inc., Board Appoints Howard J. Leonhardt Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 2015  BioClinica®, Inc., a leading specialty ... announced that clinical trial professionals representing 20 ... annual European User Conference in ... use of its eClinical technologies to overcome ... the Microsoft Office-Smart OnPoint CTMS; Express EDC; ...
(Date:3/4/2015)... California (PRWEB) March 04, 2015 ... (PCR) represents one of the fastest growing technologies in ... biologists in subcellular visualization is driving growth in nucleic ... for deeper understanding of gene expressions will continue to ... Expanding applications in fields ranging from pharma, biotech, food ...
(Date:3/4/2015)... 2015 Lancée par ... en décembre 2011, l,étude collaborative française ... qui compare   l es microsphères en ... dans le carcinome hépatocellulaire avancé, a recruté plus ... avancé   ; les résultats sont attendus fin ...
(Date:3/3/2015)... SAN DIEGO and TORONTO, March 3, 2015 /PRNewswire/ - ... company developing new therapeutics and molecular diagnostics that target ... for the quarter and seventh-month period ended December 31, ... changed its fiscal year end from May 31 to ... periods we are reporting today are for the quarter ...
Breaking Biology Technology:BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12
... SAN FRANCISCO, Sept. 3 Osprey Pharmaceuticals ... protein therapeutics,that selectively target chemokine-activated leukocytes that ... announced today that,the company has raised $11 ... capital,funding. The financing was led by Burrill ...
... NANJING, China, Sept. 3 ,Acesys Pharmatech and Provid ... discovery expertise and project management,capabilities of Provid in ... cost structure of Acesys in China., The ... all,aspects of medicinal chemistry for clients in the ...
... TUSTIN, Calif., Sept. 3 Peregrine,Pharmaceuticals, Inc. (Nasdaq: ... results for the first quarter of fiscal year 2009 ... host a conference call and,webcast to discuss the results ... Peregrine,s senior management will discuss financial results for the,first ...
Cached Biology Technology:Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing 2Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing 3Acesys and Provid Announce Alliance for Medicinal Chemistry Services 2Peregrine Pharmaceuticals to Report First Quarter FY 2009 Financial Results 2
(Date:2/5/2015)... 26, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market, ... http://www.nxt-id.com/ ) as part of its 2015 marketing and ... launched its new consumer website for Wocketwallet.com earlier this ... of NXT-ID said, "Our new corporate website naturally showcases ...
(Date:2/5/2015)... , Jan. 28, 2015 Research and Markets ... addition of the "Global Biometrics Market (2014-2020): ... and Countries " report to their offering. ... Asia-Pacific is anticipated to overtake ... owing to increasing government spending towards IT security, ...
(Date:1/22/2015)... Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to ... State of Washington,s Department of Licensing, in ... central issuance system for driver,s licenses and identification cards to ... and development will start in January 2015, with enrollment and ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Valid USA Signs Contract For Washington Driver's License Issuance 2
... malaria, TB & HIV/AIDS cause more than five million deaths ... of Washington and represent one of the world,s major ... of the 21st century. In the May 26, 2011, edition ... Director Alan Aderem, Ph.D., along with Rino Rappuoli, Ph.D., Global ...
... MASS.One helpful action anyone can take in response to ... Trees and plants capture carbon dioxide during photosynthesis, thereby ... and storing some of it in their woody tissue. ... of trees to store carbon by altering forest nitrogen ...
... Species Exploration at Arizona State University and a committee ... for the top 10 new species described in 2010. ... a pancake batfish recently discovered by Prosanta Chakrabarty, curator ... colleagues. Halieutichthys intermedius , more commonly referred to ...
Cached Biology News:2020 vision of vaccines for malaria, TB and HIV/AIDS 2Global warming may affect the capacity of trees to store carbon, MBL study finds 2Fish species discovered by LSU researcher makes 2011 top 10 list 2
Mouse monoclonal antibody raised against a partial recombinant QARS. NCBI Entrez Gene ID = QARS...
Mouse monoclonal antibody raised against a partial recombinant QPCT. NCBI Entrez Gene ID = QPCT...
... Researchers no longer need to perform time consuming ... With Mutation Surveyor, any found variants of the ... clearly indicated in our mutation electropherogram as a ... the bi-directional analysis mode is over 99%, with ...
... 220-240 V, is used for biolistic particle delivery ... an adjustable helium pulse to sweep DNA-, RNA-, ... wall of a small plastic cartridge directly into ... in situ, in vitro, in vivo, and ex ...
Biology Products: